Oral Semaglutide Did Not Slow Alzheimer's Progression in Phase 3 (EVOKE / EVOKE+); GLP-1 Agonists Retain Cardiovascular + Metabolic + Parkinson Phase-2 Signals

GLP-1 agonists have demonstrated cardiovascular and metabolic benefits in large Phase 3 trials, but oral semaglutide did not meet its primary endpoint in Phase 3 trials of early Alzheimer's disease. A separate Phase 2 trial of lixisenatide showed a motor-progression signal in ear

Type

evidence-claim

Domain

h11_chronic_inflammation

Grade

A

License

CC BY-NC 4.0

card_id

L-006

hallmarks

h11_chronic_inflammation,h06_deregulated_nutrient_sensing

cluster

clinical_translation

primary_disease_area

alzheimers,parkinsons,longevity_general

evidence_tier

A

evidence_anchor_count

6

intake_round

R23

intake_date

2026-05-26

related_experts

related_biomarkers

related_interventions

int_semaglutide,int_lixisenatide

related_trials

trial_nct04777396_evoke,trial_nct04777409_evoke_plus,trial_nct03574597_select,trial_lixisenatide_pd_phase2

collection_pages

/research/trials,/research/clinical-translation

LongProof Longevity Dynamic · LIGHT HOPE / x1000.ai · longevity.x1000.ai · 2026 · source

Read-only aggregated view. Longevity Evidence is the source of record; this catalog shows provenance as-is — no ratings, no reviews.